Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Molybdenum cofactor biosynthesis enzymes comprise a sequence of highly conserved proteins responsible for synthesizing the pterin-based molybdenum cofactor (Moco), which is vital for the activity of all molybdenum-dependent oxidoreductases. In plants and mammals, these include enzymes such as CNX1, CNX2, CNX3, and in bacteria, MogA and MoeA, among others. The biosynthesis is a complex, multi-step pathway involving the formation of molybdopterin, its adenylation, and insertion of molybdenum, typically carried out by dedicated enzymatic complexes often associated with cytoskeletal structures for efficient substrate channelling. Defects in genes encoding these enzymes are responsible for rare but severe inherited metabolic diseases[1][2][3][4]. The pathway itself is not a direct drug target, but understanding its biology is essential for managing Moco deficiency disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Molybdenum cofactor biosynthesis pathway enzymes.